Zydus nabs FDA approval for type-2 diabetes drug
pharmafile | July 11, 2016 | News story | Sales and Marketing |Â Â Zydus Cadila, nateglinideÂ
Zydus Cadila, a division of Cadila Pharmaceuticals (NSE: CADILAHC), has announced the US Food and Drug Administration (FDA) has approved type-2 diabetes drug, nateglinide tablets USP, in strengths of 60mg and 120mg.
Marketed by Novartis as Starlix, nateglinide is an oral antidiabetic agent used in the management of type-2 diabetes mellitus.
Zydus Cadila will produce the drug at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. They indicate that the group now has more than 100 approvals and has so far filed 270 ANDAs since the commencement of the filing process in 2003-4.
Sean Murray
Related Content

Cadila and Supernus settle patent dispute over epilepsy generic
A patent dispute between Indian pharmaceutical firm Cadila Healthcare and US-based Supernus Pharmaceuticals has been …

Zydus Cadila scores twin FDA approvals
Indian pharmaceutical firm Zydus Cadila has announced that the US Food and Drug Administration (FDA) …

Takeda partners with Zydus to develop chikungunya vaccine
Zydus Cadila has teamed up with Takeda to develop a vaccine for the chikungunya virus. …






